Myocardial Protection Effect of Simvastatin Undergoing Cardiac Surgery
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01653223 |
Recruitment Status
:
Recruiting
First Posted
: July 30, 2012
Last Update Posted
: April 25, 2017
|
Sponsor:
Sun Yat-sen University
Information provided by (Responsible Party):
Jing-song Ou, Sun Yat-sen University
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | July 26, 2012 | ||||||||
First Posted Date ICMJE | July 30, 2012 | ||||||||
Last Update Posted Date | April 25, 2017 | ||||||||
Study Start Date ICMJE | January 2013 | ||||||||
Estimated Primary Completion Date | December 2018 (Final data collection date for primary outcome measure) | ||||||||
Current Primary Outcome Measures ICMJE |
troponin [ Time Frame: within the first 7 days after surgery ] The investigator will measure the plasma troponin level in several time points before and after surgery in each patient.
|
||||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||||
Change History | Complete list of historical versions of study NCT01653223 on ClinicalTrials.gov Archive Site | ||||||||
Current Secondary Outcome Measures ICMJE |
ejection fraction [ Time Frame: within two years ] Each patient will be followed up and checked with B ultrasound on heart in 1,3,6,12,18 and 24 months after surgery. The ejection fraction will be measured
|
||||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||||
Current Other Outcome Measures ICMJE |
long term survival [ Time Frame: within two years ] Each patient will be followed up and observed survival time.
|
||||||||
Original Other Outcome Measures ICMJE | Same as current | ||||||||
Descriptive Information | |||||||||
Brief Title ICMJE | Myocardial Protection Effect of Simvastatin Undergoing Cardiac Surgery | ||||||||
Official Title ICMJE | A Study of Simvastatin on Myocardial Protection and Cardiac Function Undergoing Cardiac Surgery With Cardiopulmonary Bypass | ||||||||
Brief Summary | Statins have been used to low cholesterol to prevent and treat coronary artery diseases. It was also reported that statins could protect endothelial function and cardiac function during coronary artery bypass graft. We recent found simvastatin reduced myocardial injury during noncoronary artery cardiac surgery in single medical center. We further investigate that whether simvastatin can protect myocardium during noncoronary artery cardiac surgery with cardiopulmonary bypass and improve cardiac function with long term use postoperatively in two medical centers. | ||||||||
Detailed Description | Not Provided | ||||||||
Study Type ICMJE | Interventional | ||||||||
Study Phase | Not Applicable | ||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Prevention |
||||||||
Condition ICMJE |
|
||||||||
Intervention ICMJE | Drug: simvastatin
In short statin group: 20 mg per day, start at 5-7 days before surgery and continue for 7 days. In long statin group: 20 mg per day, start at 5-7 days before surgery and continue for 6 months. Other Name: simcor |
||||||||
Study Arms |
|
||||||||
Publications * | Not Provided | ||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status ICMJE | Recruiting | ||||||||
Estimated Enrollment ICMJE |
369 | ||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||
Estimated Study Completion Date | December 2020 | ||||||||
Estimated Primary Completion Date | December 2018 (Final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||
Sex/Gender |
|
||||||||
Ages | 18 Years and older (Adult, Senior) | ||||||||
Accepts Healthy Volunteers | No | ||||||||
Contacts ICMJE |
|
||||||||
Listed Location Countries ICMJE | China | ||||||||
Removed Location Countries | |||||||||
Administrative Information | |||||||||
NCT Number ICMJE | NCT01653223 | ||||||||
Other Study ID Numbers ICMJE | statin2 5010-2012001 ( Other Grant/Funding Number: Sun Yat-sen University ) 5010-2014002 ( Other Grant/Funding Number: Sun Yat-sen University ) |
||||||||
Has Data Monitoring Committee | Yes | ||||||||
U.S. FDA-regulated Product | Not Provided | ||||||||
IPD Sharing Statement | Not Provided | ||||||||
Responsible Party | Jing-song Ou, Sun Yat-sen University | ||||||||
Study Sponsor ICMJE | Sun Yat-sen University | ||||||||
Collaborators ICMJE | Not Provided | ||||||||
Investigators ICMJE |
|
||||||||
PRS Account | Sun Yat-sen University | ||||||||
Verification Date | April 2017 | ||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |